Importance

Loading Importance Indicators...

Abstract

Ar is optionally substituted with 1 to 3 R.sub.X groups, and where n is 0, 1, 2 or 3; and a group of formula III: 1 herein: R.sup.4 is selected from hydrogen; and straight or branched alkyl; R.sup.5 is selected from hydrogen; straight, branched, unsaturated or alicyclic alkyl, optionally substituted with 1 to 3 R.sub.X groups, where the alkyl group is optionally interrupted by X, where X is selected from O, S, NH and N(COCH.sub.3); allyloxy and 9-fluorenylmethyloxy; and (CH.sub.2).sub.nAr, where Ar is selected from phenyl, furanyl, thienyl, pyridyl, naphthyl, biphenyl, dibenzofuranyl, dibenzothienyl, fluorenyl and fluorenonyl, where n is 0, 1, 2 or 3, and where Ar is optionally substituted with 1 to 3 R.sub.X groups; and R.sub.X is selected from OR, CN, C(O)NH.sub.2, C(O)NHR, C(O)N(R).sub.2, OC(O)NH.sub.2, OC(O)R, CHO, SO.sub.2NH.sub.2, SOR, CF.sub.3, C(O)R, COOR, F, Cl, Br, I, OCH.sub.2Ph, NHR, N(R).sub.2,, NHCOR, NHCO.sub.2t-Bu, NHCO.sub.2allyl, NH.sub.2, and R, where R is hydrogen, C.sub.1 to C.sub.15 alkyl, or aryl. The invention is further directed to a pharmaceutical composition containing the compound, as well as a method for treating bacterial infections in animals or humans, wherein the composition can be administered in combination with a .beta.-lactam antibiotic.

Loading the Abstract Image...

First Claim